Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 17, 2025 16:05 ET | Source: Cardiff Oncology, Inc.

Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC

– Veteran executive with over 20 years of oncology leadership and clinical experience with proven track record of success in bringing development candidates through late-stage clinical development – ...
May 13, 2025 13:00 ET | Source: DelveInsight Business Research LLP

Metastatic Colorectal Cancer Clinical Trial Pipeline Accelerates as 150+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

New York, USA, May 13, 2025 (GLOBE NEWSWIRE) -- Metastatic Colorectal Cancer Clinical Trial Pipeline Accelerates as 150+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight ...
November 20, 2024 07:30 ET | Source: FACT.MR

Metastatic Colorectal Cancer Market Forecast to Reach US$ 9,787.5 Million by 2034, Growing at 5.1% CAGR | Fact.MR Report

Rockville, MD, Nov. 20, 2024 (GLOBE NEWSWIRE) -- According to Fact.MR, a market research and competitive intelligence provider, the global metastatic colorectal cancer market is estimated to reach a...
October 12, 2023 08:00 ET | Source: Rationalstat LLC

Metastatic Colorectal Cancer Therapeutics Market Set to Touch US$ 8.7 Billion by 2030, According to RationalStat Published Report

Wilmington, Delaware, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Global Metastatic Colorectal Cancer Therapeutics Market is estimated at a market value of US$ 5.9 billion in 2023 and is predicted to rise at...
October 06, 2021 20:00 ET | Source: DelveInsight Business Research LLP

Metastatic Colorectal Cancer Pipeline Review | Clinical Trials Analysis Report 2021 | DelveInsight

Los Angeles, USA, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Metastatic Colorectal Cancer Pipeline Review | Clinical Trials Analysis Report 2021 | DelveInsight Metastatic Colorectal Cancer Pipeline is...
June 08, 2021 09:15 ET | Source: Processa Pharmaceuticals, Inc.

Processa Set to Join Russell Microcap® Index

HANOVER, MD, June 08, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve...
September 10, 2020 07:45 ET | Source: HalioDx

Immunoscore® to select patients in the POCHI trial, a phase II multicenter trial testing immunotherapy with chemotherapy and bevacizumab in metastatic colorectal cancer

Immunoscore® to select patients in the POCHI trial, a phase II multicenter trial testing immunotherapy with chemotherapy and bevacizumab in metastatic colorectal cancer Marseille, France, September...
June 01, 2020 09:00 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Announces Presentation of Updated Data from Metastatic Uveal Melanoma Cohort of Phase 1 PV-10® Study at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program

Treatment refractory, immunologically cold, hepatic tumor type37% reduction and 83% stabilization of treated disease (2D-EASL)Overall survival of 11 months for checkpoint inhibition-naïve patients;...
June 01, 2020 07:00 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Announces Publication of Updated Data from Metastatic Neuroendocrine Phase 1 PV-10® Study at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program

Treatment refractory, immunologically cold, hepatic tumor type50% reduction of treated disease; 83% stabilization of overall patient disease (RECIST)Median progression-free survival not reached (by CT...
November 08, 2017 16:01 ET | Source: Cascadian Therapeutics, Inc.

Cascadian Therapeutics Reports Third Quarter 2017 Financial Results

SEATTLE, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter ended...